TKNO Earnings Date: Nov 4, 2026 (Estimated) — Alpha Teknova, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is TKNO's next earnings date?
Alpha Teknova, Inc. (TKNO) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.06 on revenue of $11.7M.
How did TKNO do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Alpha Teknova, Inc. posted EPS of -$0.06 versus the -$0.08 estimate, a beat of 14.3%. Revenue was $12.2M against a $11.0M estimate. The stock's 1-day post-earnings move was +16.4%.
How much does TKNO stock move after earnings?
TKNO beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.2% (up or down) in the day after earnings.
About Alpha Teknova, Inc.
Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of biopharmaceutical goods, such as advanced drug treatments, new vaccines, and molecular diagnostic solutions. The company's product offerings encompass pre-filled media plates designed for cell growth and replication; liquid cell culture media and complementary supplements that promote cellular proliferation; and various molecular biology reagents used for the handling, rehydration, and purification of samples. Teknova caters to a diverse clientele within the life sciences arena, including pharmaceutical companies, biotechnology firms, contract development and manufacturing organizations (CDMOs), in vitro diagnostic businesses, and academic and governmental research facilities. Founded in 1996, Alpha Teknova's main office is situated in Hollister, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.08 | -0.06 | +14.29% | $12.2M | ✅ Beat | +16.40% | +31.73% | +29.06% |
| 2026-05-06 | Q1 2026 | -0.09 | -0.08 | +11.11% | $11.1M | ✅ Beat | +9.89% | +7.42% | +25.27% |
| 2026-02-26 | Q4 2025 | -0.09 | -0.09 | +0.00% | $10.0M | ➖ Inline | +13.16% | -3.07% | +18.86% |
| 2025-11-06 | Q3 2025 | -0.09 | -0.08 | +11.11% | $10.5M | ✅ Beat | -2.08% | -7.90% | -4.78% |
| 2025-03-04 | Q4 2024 | -0.12 | -0.11 | +8.33% | $9.3M | ✅ Beat | -1.16% | -10.93% | -9.60% |
| 2024-11-07 | Q3 2024 | -0.11 | -0.15 | -36.36% | $9.6M | ❌ Miss | +3.92% | -4.79% | +22.50% |
| 2024-08-13 | Q2 2024 | -0.16 | -0.13 | +18.75% | $9.6M | ✅ Beat | -6.55% | +24.43% | +14.86% |
| 2024-05-13 | Q1 2024 | -0.24 | -0.20 | +16.67% | $9.3M | ✅ Beat | +12.07% | +2.87% | +0.00% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $12.2M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Lab Essentials | 75.4% | $9.2M | +17.9% | $6.8M | $8.1M | $7.8M | $8.3M |
| Clinical Solutions | 19.9% | $2.4M | +17.9% | $1.9M | $1.2M | $2.1M | $1.7M |
| Other Product | 4.7% | $573K | +31.7% | $597K | $516K | $435K | $440K |
By region
Q2 FY26 · $12.2M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 95.7% | $11.7M | +19.2% | $8.8M | $9.3M | $9.8M | $9.8M |
| Non-US | 4.3% | $526K | +3.1% | $501K | $523K | $510K | $622K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.